GeckoSystems Intl. Corp. (PINKSHEETS: GCKO) (http://www.geckosystems.com/) announced in their press release today that since Sprint Nextel Corporation has finalized their contractual terms and conditions, Gecko can more expediently complete their first elder care robot trials. This announcement follows their press release last month stating they were in negotiations with a Fortune 500 company. As a result of this agreement , Gecko’s elder care robot trial participants will receive special pricing from Sprint Nextel; the trials have been underway since late 2009.
GCKO opened yesterday at $0.015 and closed at $0.0165 which is an increase of 10%; the volume over the past few days has also been rising. I wonder if this diamond in the rough is soon to be a polished stone. Better yet, a flawless polished stone. I'm holding my position long term.
Remember that since GCKO is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Thursday, July 22, 2010
Wednesday, July 21, 2010
Cannabis Science, Inc. (OTCBB:CBIS)
Cannabis Science, Inc. is a pioneering U.S. biotech company developing pharmaceutical cannabis products.
California’s Proposition 19, the legalization of cannabis products, has been a heavily debated topic as of late. If you have trouble sleeping go to the following web site to read all about Proposition 19 - http://www.sos.ca.gov/elections/ballot-measures/qualified-ballot-measures.htm. If that doesn’t put you to sleep, the website includes several other California propositions you can read about.
As I delved into the mountains of information surrounding the topic I came across a company called Cannabis Science, Inc. (CBIS). Their website defines the company as a pioneering U.S. biotech company developing pharmaceutical cannabis products. I perused their press releases and below is my synopsis of several of them along with other information. My synopsis only includes the information from the press releases that I chose to share in this posting. If you would like to review the full press release go to the CBIS website: http://www.cannabisscience.com
March 2, 1010
CBIS announced that they have the results of their survey of more than 1,300 individuals with Post Traumatic Stress Disorder (PTSD) which included a large cohort of veterans. They also reported several prospective drugs for FDA clinical trials. As a result of the survey data and other extensive studies, CBIS said they now have the data necessary their first application for a PTSD drug for FDA clinical trials; the Company plans to hire a group of FDA specialists to handle their first FDA filings.
March 4, 2010
CBIS announced that it has set its second FDA drug target on the $20 Billion "Chronic Pain" market and plan to launch a new survey of cannabis use by chronic pain patients to gather additional first hand information from all chronic pain suffers. You can find a list of drug targets on the CBIS website.
May 24, 2010
CBIS acquired 100% of a private company with two revenue producing operations, an organic medical cannabis growing facility and a medical cannabis dispensary for patients in Colorado in accordance with state laws. This added income provides CBIS with a revenue stream much sooner than otherwise possible and they plan to expand them by acquiring a larger facility which will enhance their ability to develop pharmaceutical cannabis products for FDA approval. The company issued 2.4 million shares to pay for the acquisition of the operations and as compensation for a management contract. Currently, there are 64,570,574 shares outstanding and management expects to retire most of its debt by the end of June 2010 to eliminate a major source of risk. The former owner, Mr. Adam Pasquale, is joining the CBIS as Director of Horticulture with responsibility for managing these operations and the implementation of CBIS’s plan to expand these areas nationally, as the laws allow. As of July 21, 2010, they still have 64,570,574 shares outstanding.
June 1, 2010
Dr. Robert Melamede said that CBIS is negotiating the purchase of a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. He went on to say that they filed a preliminary patent disclosure with the University of Colorado regarding the additional new technology they intend to develop through the targeted private company acquisitions and plan to hire a patent attorney to help with the University disclosure and ultimate patent filings. Additionally, they are working with FDA consultants in their quest to obtain FDA approval for several new pharmaceutical products they believe can be derived from this deal. Dr. Melamede said efforts to identify and consolidate various new technologies aimed at developing pharmaceutical cannabis products for critical illnesses and worldwide distribution would continue.
June 28, 2010
CBIS said they viewed UK-based GW Pharmaceuticals receipt of a $15 million milestone payment from Bayer as an important signpost for the continued validation of medical cannabis. According to the press release, the payment to GW was based on the UK Government's approval of GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS) and is the first cannabis drug to be approved in the UK. According to Piper Jaffary analysts, peak sales for Sativex(R) could reach $180 million in Europe and Canada combined. The release mentioned that the US FDA previously granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain, GW’s receipt of an 18 million dollar licensing fee from Otsuka for the US rights and the receipt of several million from licensing fees from Almiral of Spain for the European rights outside of the UK which included payment for the work necessary to obtain regulatory approval. In a nutshell, it appears that Big Pharma has recognized the potential of this industry and wants a piece of the action. Additionally, the approval sativex(R) by the FDA could potentially lead to the fast-tracking of other whole cannabis extracts.
June 29, 2010
Dr. Robert Melamede PhD, President and CEO of CBIS, said that the expansion of the internal production of CBIS at their Montana Pain Management (MPM) facility would allow them to expand their patient base by 100 new clients each month and help advance their objectives in developing pharmaceutical applications for medical CBIS. He further stated that the coupling of the internal production facility, MPM’s agricultural staff and CBIS’s scientists and commercial production staff aggressively positions CBIS to be a key player in the developing national medical CBIS industry. The release also mentioned that Montana officials were working with Rick Rosio, President and CEO of MPM, to develop policies that protect patients and help them access the medicines they need. An early June press release announced the acquisition of MPM by CBIS in June 2010.
July 8, 2010
CBIS announced their execution of a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and production in compliance with the new Colorado laws regulating medical marijuana in the state. What intrigued me was the mention of the “long-term” lease.
According to the CBIS website, several states have already approved cannabis for medicinal approval. From all indications, California is well on their way to approving Proposition 19. If it passes in California and has a positive impact on their troubled economic condition, I wonder how many other troubled states would follow suit? If it does, it appears as though CBIS is doing everything possible to hit the ground running when the time comes.
California’s Proposition 19, the legalization of cannabis products, has been a heavily debated topic as of late. If you have trouble sleeping go to the following web site to read all about Proposition 19 - http://www.sos.ca.gov/elections/ballot-measures/qualified-ballot-measures.htm. If that doesn’t put you to sleep, the website includes several other California propositions you can read about.
As I delved into the mountains of information surrounding the topic I came across a company called Cannabis Science, Inc. (CBIS). Their website defines the company as a pioneering U.S. biotech company developing pharmaceutical cannabis products. I perused their press releases and below is my synopsis of several of them along with other information. My synopsis only includes the information from the press releases that I chose to share in this posting. If you would like to review the full press release go to the CBIS website: http://www.cannabisscience.com
March 2, 1010
CBIS announced that they have the results of their survey of more than 1,300 individuals with Post Traumatic Stress Disorder (PTSD) which included a large cohort of veterans. They also reported several prospective drugs for FDA clinical trials. As a result of the survey data and other extensive studies, CBIS said they now have the data necessary their first application for a PTSD drug for FDA clinical trials; the Company plans to hire a group of FDA specialists to handle their first FDA filings.
March 4, 2010
CBIS announced that it has set its second FDA drug target on the $20 Billion "Chronic Pain" market and plan to launch a new survey of cannabis use by chronic pain patients to gather additional first hand information from all chronic pain suffers. You can find a list of drug targets on the CBIS website.
May 24, 2010
CBIS acquired 100% of a private company with two revenue producing operations, an organic medical cannabis growing facility and a medical cannabis dispensary for patients in Colorado in accordance with state laws. This added income provides CBIS with a revenue stream much sooner than otherwise possible and they plan to expand them by acquiring a larger facility which will enhance their ability to develop pharmaceutical cannabis products for FDA approval. The company issued 2.4 million shares to pay for the acquisition of the operations and as compensation for a management contract. Currently, there are 64,570,574 shares outstanding and management expects to retire most of its debt by the end of June 2010 to eliminate a major source of risk. The former owner, Mr. Adam Pasquale, is joining the CBIS as Director of Horticulture with responsibility for managing these operations and the implementation of CBIS’s plan to expand these areas nationally, as the laws allow. As of July 21, 2010, they still have 64,570,574 shares outstanding.
June 1, 2010
Dr. Robert Melamede said that CBIS is negotiating the purchase of a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. He went on to say that they filed a preliminary patent disclosure with the University of Colorado regarding the additional new technology they intend to develop through the targeted private company acquisitions and plan to hire a patent attorney to help with the University disclosure and ultimate patent filings. Additionally, they are working with FDA consultants in their quest to obtain FDA approval for several new pharmaceutical products they believe can be derived from this deal. Dr. Melamede said efforts to identify and consolidate various new technologies aimed at developing pharmaceutical cannabis products for critical illnesses and worldwide distribution would continue.
June 28, 2010
CBIS said they viewed UK-based GW Pharmaceuticals receipt of a $15 million milestone payment from Bayer as an important signpost for the continued validation of medical cannabis. According to the press release, the payment to GW was based on the UK Government's approval of GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS) and is the first cannabis drug to be approved in the UK. According to Piper Jaffary analysts, peak sales for Sativex(R) could reach $180 million in Europe and Canada combined. The release mentioned that the US FDA previously granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain, GW’s receipt of an 18 million dollar licensing fee from Otsuka for the US rights and the receipt of several million from licensing fees from Almiral of Spain for the European rights outside of the UK which included payment for the work necessary to obtain regulatory approval. In a nutshell, it appears that Big Pharma has recognized the potential of this industry and wants a piece of the action. Additionally, the approval sativex(R) by the FDA could potentially lead to the fast-tracking of other whole cannabis extracts.
June 29, 2010
Dr. Robert Melamede PhD, President and CEO of CBIS, said that the expansion of the internal production of CBIS at their Montana Pain Management (MPM) facility would allow them to expand their patient base by 100 new clients each month and help advance their objectives in developing pharmaceutical applications for medical CBIS. He further stated that the coupling of the internal production facility, MPM’s agricultural staff and CBIS’s scientists and commercial production staff aggressively positions CBIS to be a key player in the developing national medical CBIS industry. The release also mentioned that Montana officials were working with Rick Rosio, President and CEO of MPM, to develop policies that protect patients and help them access the medicines they need. An early June press release announced the acquisition of MPM by CBIS in June 2010.
July 8, 2010
CBIS announced their execution of a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and production in compliance with the new Colorado laws regulating medical marijuana in the state. What intrigued me was the mention of the “long-term” lease.
According to the CBIS website, several states have already approved cannabis for medicinal approval. From all indications, California is well on their way to approving Proposition 19. If it passes in California and has a positive impact on their troubled economic condition, I wonder how many other troubled states would follow suit? If it does, it appears as though CBIS is doing everything possible to hit the ground running when the time comes.
Thursday, July 8, 2010
GeckoSystems (GCKO)
7/8/10 – GeckoSystem Int’l announced that the international market research firm, Markets and Markets, forecasted $21 billion in annual sales for the global service robotics market by end of 2014.
06/30/10 - GeckoSystem Int’l announced that they are now soliciting retail dealers for their first product, an elder care capable personal assistant robot, the CareBot™. The press release also mentioned the article in the January 2007 issue of "Scientific American," entitled "A Robot in Every Home" authored by Bill Gates which includes discussions as to why he expects that reality sooner than later.
6/21/1010 - GeckoSystem Int’l announced that a major US telecommunications company considers GeckoSystems to have strategic fit within their New Solutions Group. Due to on-going negotiations, the name of the future partner was not disclosed.
I still firmly believe that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. The timing for setting up distributorships now, in my opinion, is aligned with the needs of the aging baby boomer population. Who knows, a CareBot™ in th e homes of aging baby boomers could be a part of the realm of reality projected by Bill Gates. As soon as one of the “big boys” discovers the potential of this stock and begins making purchases, the doors for the other big players will swing wide open and the share price we see today will be left behind in the dust of the stampede.
The future prospect of the CareBot™ continues to excite me and I hope I can acquire more GCKO stock before this hidden gem is uncovered. It closed green today – is the steam starting to build?
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
06/30/10 - GeckoSystem Int’l announced that they are now soliciting retail dealers for their first product, an elder care capable personal assistant robot, the CareBot™. The press release also mentioned the article in the January 2007 issue of "Scientific American," entitled "A Robot in Every Home" authored by Bill Gates which includes discussions as to why he expects that reality sooner than later.
6/21/1010 - GeckoSystem Int’l announced that a major US telecommunications company considers GeckoSystems to have strategic fit within their New Solutions Group. Due to on-going negotiations, the name of the future partner was not disclosed.
I still firmly believe that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. The timing for setting up distributorships now, in my opinion, is aligned with the needs of the aging baby boomer population. Who knows, a CareBot™ in th e homes of aging baby boomers could be a part of the realm of reality projected by Bill Gates. As soon as one of the “big boys” discovers the potential of this stock and begins making purchases, the doors for the other big players will swing wide open and the share price we see today will be left behind in the dust of the stampede.
The future prospect of the CareBot™ continues to excite me and I hope I can acquire more GCKO stock before this hidden gem is uncovered. It closed green today – is the steam starting to build?
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
Friday, May 28, 2010
GeckoSystems International Corp GCKO:OTC
Currently, I am dealing with a parent that requires assisted living. Watching her heart break because she can no longer live in her home of thirty plus years has proven to be emotionally trying. I have also learned that growing old is definitely not for the weak hearted.
As much as I wanted her to remain in her home, a full time in home care giver was not a financial option. As I researched viable alternatives, I discovered Gecko Systems (GCKO.OTC). Gecko is a Based in Atlanta, GA, and sells the CareBot™ line of Mobile Service Robots for the elderly care market. Although it is still in the developmental stage, I think such a device has the potential to eventually become a financially affordable in home care giver. I am of the opinion that the robotic trend will have a significant impact on the lives of the elderly and of people in general for generations to come and GCKO is on the ground floor with unlimited potential.
The iRobot Corp published a press release in January 2010 that indicated it has sold more than 5 million Roombas (home robot vacuums) worldwide since 2002. According to a 2009 report by ABI Research, by the year 2015 personal robot sales in the U.S. will exceed $5B and singles out North America as the largest market for personal robots followed by Japan.
When you consider the liquid nature of technological advancement, I strongly believe the consumer robot market will come to fruition sooner than later. New robots will have more computing power, an improved knowledge base, wireless capabilities and enhanced speech recognition. They will also have the ability to interact with individuals, help them make decisions and express basic emotions. While it is true that human interaction still represents one of the most valued human experiences, the CareBot™ enables family members to personally record the daily reminders and commands. It’s not perfect, but it is a step in the right direction.
There is no doubt in my mind that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. Additionally, as the baby boomers become the "elderly population", the market for such a device will increase proportionally. I am excited by these future prospects and plan on acquiring as much GCKO stock as I can before this hidden gem is uncovered.
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
As much as I wanted her to remain in her home, a full time in home care giver was not a financial option. As I researched viable alternatives, I discovered Gecko Systems (GCKO.OTC). Gecko is a Based in Atlanta, GA, and sells the CareBot™ line of Mobile Service Robots for the elderly care market. Although it is still in the developmental stage, I think such a device has the potential to eventually become a financially affordable in home care giver. I am of the opinion that the robotic trend will have a significant impact on the lives of the elderly and of people in general for generations to come and GCKO is on the ground floor with unlimited potential.
The iRobot Corp published a press release in January 2010 that indicated it has sold more than 5 million Roombas (home robot vacuums) worldwide since 2002. According to a 2009 report by ABI Research, by the year 2015 personal robot sales in the U.S. will exceed $5B and singles out North America as the largest market for personal robots followed by Japan.
When you consider the liquid nature of technological advancement, I strongly believe the consumer robot market will come to fruition sooner than later. New robots will have more computing power, an improved knowledge base, wireless capabilities and enhanced speech recognition. They will also have the ability to interact with individuals, help them make decisions and express basic emotions. While it is true that human interaction still represents one of the most valued human experiences, the CareBot™ enables family members to personally record the daily reminders and commands. It’s not perfect, but it is a step in the right direction.
There is no doubt in my mind that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. Additionally, as the baby boomers become the "elderly population", the market for such a device will increase proportionally. I am excited by these future prospects and plan on acquiring as much GCKO stock as I can before this hidden gem is uncovered.
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
Thursday, April 15, 2010
Update: (MCLN) MedClean Technologies, Inc
On April 15, 2010, PR Newswire reported that MedClean Technologies, Inc. (MCLN) and Verde Enterprises LLC executed a distribution agreement to provide on-site integrated medical waste disposal and document destruction services. The intent of the agreement is to pave a path for both companies to collaborate and serve approximately 250 large-quantity medical waste generators in New York and New Jersey in hopes of producing approximately $2 million in new business. I checked the MCLN website this morning, but the PR News release was not yet posted.
Here is an updated recap of MCLN’s recent strategic developments.
- Distributorship with Verde Enterprises
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
This news release served to further solidify my belief in MCLN and their ability to increase their share price over the next year or so. While the alliances are critical to the successes of MCLN, they only represent one side of the coin. Unless MCLN substantiates their claims with actual sales, the millions of dollars generated by the proposed new business represent nothing more than dreams expressed in written words.
Remember, since MCLN is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long MCLN
Here is an updated recap of MCLN’s recent strategic developments.
- Distributorship with Verde Enterprises
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
This news release served to further solidify my belief in MCLN and their ability to increase their share price over the next year or so. While the alliances are critical to the successes of MCLN, they only represent one side of the coin. Unless MCLN substantiates their claims with actual sales, the millions of dollars generated by the proposed new business represent nothing more than dreams expressed in written words.
Remember, since MCLN is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long MCLN
Wednesday, April 14, 2010
CRXX: CombinatoRx
Business Wire reported that according to the Journal of the American Society of Hematology article entitled, "Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies," Rickles, et.al., Blood First Edition Paper, prepublished online April 9, 2010; DOI 10.1182/blood-2009-11-252668, CombinatoRx (CRXX) researchers in collaboration with Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, demonstrated that the exposure of the large B-cell lymphoma cell lines to A2A agonists and specific PDE inhibitors resulted in rapid synergistic inhibition of proliferation and induction of apoptosis. Which I loosely interpret to mean cell death in cancer cells (induction of apoptosis) and stopping the spread of cancer cells (inhibition of proliferation).
Currently, CRXX is above both its 50 day and 200 day moving averages of $1.27 and $1.19 respectively and opened with a gap on April 14, 2010 at $1.48 after a previous day close of $1.33. Does this mean that CRXX is going to experience some earth shaking success in the near future?
Below is some information on three of the products in the CRXX pipeline that I obtained from their website and news releases:
Exalgo ™: the FDA approved the New Drug Application (NDA) for Exalgo ™ extended release tablets on March 1, 2010 which triggered a $40 million milestone payment to CombinatoRx from Covidien and a 44% increase in the share price of CRXX before the opening bell. Covidien acquired the commercial rights to Exalgo ™ in June 2009 and has responsibility for all marketing and sales of the product in the United States. CRXX is eligible to receive tiered royalties on net sales of Exalgo ™.
Prednisporin™ is a topical ocular drug for the treatment of flammatory ocular diseases such as conjunctivitis which CominatoRx has exclusively licensed to Fovea Pharmaceuticals. In 2009, Fovea conducted a Phase 2a proof-of-concept clinical trial in the United States in approximately 150 patients and reported no adverse events.
CRx-102 (Synavive™) is intended to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, also known as a dissociated steroid. The market potential consists of an estimated 33 million osteoarthritis patients and 2 million rheumatoid arthritis patients in the United States. CRXX has completed a phase 2 study in knee osteoarthis with no serious adverse events reported from patients. The phase 2 hand study demonstrated statistically significant improvement in pain compared to the placebo.
After I considered the above information, the initiated coverage of CRXX by Liberty Analytics Co., the company’s YTD Price Performance of +60.2%, the $0.15 gap up this morning at $1.48 and a 52 week high of $2.60 on September 16, 2009, I wonder if their potential for earth shaking success could be a tsunami in the making. I’ve decided to hang on to my shares and ride out the wave.
Remember that since CRXX is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Currently, CRXX is above both its 50 day and 200 day moving averages of $1.27 and $1.19 respectively and opened with a gap on April 14, 2010 at $1.48 after a previous day close of $1.33. Does this mean that CRXX is going to experience some earth shaking success in the near future?
Below is some information on three of the products in the CRXX pipeline that I obtained from their website and news releases:
Exalgo ™: the FDA approved the New Drug Application (NDA) for Exalgo ™ extended release tablets on March 1, 2010 which triggered a $40 million milestone payment to CombinatoRx from Covidien and a 44% increase in the share price of CRXX before the opening bell. Covidien acquired the commercial rights to Exalgo ™ in June 2009 and has responsibility for all marketing and sales of the product in the United States. CRXX is eligible to receive tiered royalties on net sales of Exalgo ™.
Prednisporin™ is a topical ocular drug for the treatment of flammatory ocular diseases such as conjunctivitis which CominatoRx has exclusively licensed to Fovea Pharmaceuticals. In 2009, Fovea conducted a Phase 2a proof-of-concept clinical trial in the United States in approximately 150 patients and reported no adverse events.
CRx-102 (Synavive™) is intended to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, also known as a dissociated steroid. The market potential consists of an estimated 33 million osteoarthritis patients and 2 million rheumatoid arthritis patients in the United States. CRXX has completed a phase 2 study in knee osteoarthis with no serious adverse events reported from patients. The phase 2 hand study demonstrated statistically significant improvement in pain compared to the placebo.
After I considered the above information, the initiated coverage of CRXX by Liberty Analytics Co., the company’s YTD Price Performance of +60.2%, the $0.15 gap up this morning at $1.48 and a 52 week high of $2.60 on September 16, 2009, I wonder if their potential for earth shaking success could be a tsunami in the making. I’ve decided to hang on to my shares and ride out the wave.
Remember that since CRXX is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Tuesday, April 13, 2010
Update: MCLN - MedClean Technologies
On April 13, 2010, PR Newswire reported that MedClean Technologies, Inc. (MCLN) and Barnett Medical Services (Barnett) signed a distributor agreement to synergize the service portfolio of both firms and to target the more than 230 large quantity medical waste generators and 1,500 medium quantity medical waste generators throughout the four western states currently served by Barnett. Brett Espicha, President and CEO of Barnett said the new alliance provides them with a “cradle-to-grave” medical waste disposal service, an opportunity for both firms to achieve expected revenues of $1MM to $2MM in the first year and lays the ground work for a 10 percent market penetration prospectively.
The alliance with Barnett is one of the many recent strategic puzzle pieces Mr. Laky, President and CEO of MCLN, has pulled together to enable them to achieve their 100% compounded annual growth rate target over the next five years.
Recent Strategic Developments for MCLN
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
I am of the opinion that MCLN has the potential to increase their share price over the next year or so, however, since MCLN is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Disclosure: LA Long MCLN
The alliance with Barnett is one of the many recent strategic puzzle pieces Mr. Laky, President and CEO of MCLN, has pulled together to enable them to achieve their 100% compounded annual growth rate target over the next five years.
Recent Strategic Developments for MCLN
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
I am of the opinion that MCLN has the potential to increase their share price over the next year or so, however, since MCLN is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Disclosure: LA Long MCLN
Friday, April 9, 2010
VIAP: VIA Pharmaceuticals, Inc
Shares of VIA Pharmaceuticals, Inc (VIAP) have been toggling back and forth around $0.15 and $0.20 for the last few months. As noted on their website, their main product, VIA-2291, is an important mediator of information involved in the development and progression of atherosclerosis; VIA holds exclusive worldwide rights to develop and commercialize their product.
VIA-2291 is currently being studied in three Phase 2 clinical designed with the intent of providing proof-of-concept as early as possible in the clinical development process. While the initial plan is to target the secondary prevention market for existing adverse cardiac event patients, the product has the potential to benefit the 15 million people who suffer from atherosclerosis and cardio vascular disease. At this point, VIA-2291 is Phase III ready.
In a March 31, 2010 PR news release, VIAP announced a 63% reduction in their workforce to approximately 6 people in the business development and financial areas. This strategic move seems to be a step in the right direction since it significantly reduces over head and directs their existing funds towards core research and development.
VIA-2291 is currently being studied in three Phase 2 clinical designed with the intent of providing proof-of-concept as early as possible in the clinical development process. While the initial plan is to target the secondary prevention market for existing adverse cardiac event patients, the product has the potential to benefit the 15 million people who suffer from atherosclerosis and cardio vascular disease. At this point, VIA-2291 is Phase III ready.
In a March 31, 2010 PR news release, VIAP announced a 63% reduction in their workforce to approximately 6 people in the business development and financial areas. This strategic move seems to be a step in the right direction since it significantly reduces over head and directs their existing funds towards core research and development.
Tuesday, April 6, 2010
MedClean Technologies (MCLN.OB)
MedClean Technologies, Inc, (MCLN.OB) formerly Aduromed Industries, Inc, is in the business of providing solutions for managing medical waste on site.
According to several press releases in March 2010, the company announced a partnership with Salesconx to deploy a 15 person national medical technology sales force to launch their new MC4100/MC4200 product line and a co-marketing agreement with Green Umbrella Solutions, a premier provider of services and technology for the destruction of Hippa documents. Both of these strategic alignments, according to Dave Laky, President and CEO, MedClean Technologies, Inc, lay the ground work for them to reach their objective of 100% compounded annual growth over the next five years.
The market for medical waste treatment is delineated by customer size: Large Quantity Generators (“LQGs”), those who generate large volumes of medical waste (in excess of 100,000 pounds annually), and Small Quantity Generators (“SQGs”), (those who generate less than 100,000 pounds annually).
According to several press releases in March 2010, the company announced a partnership with Salesconx to deploy a 15 person national medical technology sales force to launch their new MC4100/MC4200 product line and a co-marketing agreement with Green Umbrella Solutions, a premier provider of services and technology for the destruction of Hippa documents. Both of these strategic alignments, according to Dave Laky, President and CEO, MedClean Technologies, Inc, lay the ground work for them to reach their objective of 100% compounded annual growth over the next five years.
The market for medical waste treatment is delineated by customer size: Large Quantity Generators (“LQGs”), those who generate large volumes of medical waste (in excess of 100,000 pounds annually), and Small Quantity Generators (“SQGs”), (those who generate less than 100,000 pounds annually).
Subscribe to:
Posts (Atom)